Destiny Pharma plc (LON:DEST – Get Free Report)’s share price reached a new 52-week low on Friday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.44 ($0.03), with a volume of 3265595 shares changing hands. The stock had previously closed at GBX 2.75 ($0.04).
Analyst Ratings Changes
Separately, Shore Capital restated a “house stock” rating on shares of Destiny Pharma in a research note on Monday, July 15th.
Check Out Our Latest Report on DEST
Destiny Pharma Price Performance
Destiny Pharma Company Profile
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
Read More
- Five stocks we like better than Destiny Pharma
- Why Are Stock Sectors Important to Successful Investing?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What is a Special Dividend?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.